This poster highlights the development of a scalable human iPSC-derived engineered heart tissue (EHT) platform, combining Ncardia’s bioreactor-generated ventricular cardiomyocytes with Propria’s MyoPod® and MyoLab® technologies to create physiologically relevant cardiac microphysiological systems.
Download it now for a closer look at:
Why integrating scalable cell manufacturing with microphysiological systems improves reproducibility and physiological relevance for cardiac research and therapeutic testing